Skip to main content
SpringerLink
Log in

Immunotherapy and Immunopotentiation

  • Chapter
Ovarian Carcinoma

  • 142 Accesses

Abstract

The modern era of tumor immunotherapy started with William B. Coley, a surgeon at Memorial Hospital in New York at the end of the last century. As stated in Chapter 27, Coley had successfully treated sarcomas using live bacteria. The treatment produced a marked febrile course resulting in some spectacular results, but unfortunately the results were inconsistent and unpredictable. He next turned to using vaccines prepared from killed bacteria and again had some success, but the therapy proved to be nonspecific. Interest waxed and waned, but advances in molecular biology and understanding of the mechanism of drugs and multiple lesions on the cell has currently resulted in a revival of interest in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  • Alexander P: Immunotherapy of cancer: experiments with primary tumors and syngeneic tumor grafts. Prog Exp Tumor Res 10: 23, 1968.

    Google Scholar 

  • Anderson JM: Immunotherapy of Cancer. Clinical Oncology. Williams & Wilkins, Baltimore, 1972, p. 193.

    Google Scholar 

  • Baldwin RW, Robins RA: Immune complexes in cancer. Cancer Immunol Immunother 4: 1, 1978.

    Google Scholar 

  • Barber HRK: Present status of tumor immunology in clinical gynecology. Am J Reprod Immunol 20: 140, 1989.

    PubMed  CAS  Google Scholar 

  • Barber HRK, Dorsett BH: The immune system in gynecologic malignancies. Mt Sinai J Med (NY) 47: 539, 1980.

    CAS  Google Scholar 

  • Barber HRK, Ioachim HL, Dorsett BM: Common antigenic component in ovarian cancer. In deWatteville HD (ed): Diagnosis and Treatment of Ovarian Neoplastic Alterations. Elsevier, Amsterdam, 1975, p. 107.

    Google Scholar 

  • Bast RC Jr, Zbar B, Borson T, Rapp HL: BCG and cancer. N Engl J Med 290: 1413, 1974.

    Article  PubMed  Google Scholar 

  • Biggs PM, Churchill AE, Rootes DG, Chubb RC: The etiology of Marek’s disease in oncogenic herpes-type virus. In Pollard M (ed): Perspectives of Virology. Academic Press, Orlando, Fl, 1968, p. 211.

    Google Scholar 

  • Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas with a report of original cases. Am J Med Sci 105: 487, 1893.

    Article  Google Scholar 

  • Coley WB: Late results of treatment of inoperable sarcoma with mixed toxins of erysipelas and bacillus prodigeons. Trans Am Surg Ann 19: 27, 1901.

    Google Scholar 

  • Cunningham TJ, Olson KB, Laffin R, et al: Treatment of advanced cancer with active immunization. Cancer 24: 932, 1969.

    Article  PubMed  CAS  Google Scholar 

  • Currie GA: Eight years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer 26: 141, 1972.

    Article  PubMed  CAS  Google Scholar 

  • Currie GA, Bagshave KD: Active immunotherapy with Cornybacterium parvum and chemotherapy in murine fibrosarcoma. Br Med J 1: 541, 1970.

    Article  PubMed  CAS  Google Scholar 

  • Donahue PK, Swann DA, Hayashi A, Sullivan MD: Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science 205: 913, 1979.

    Article  Google Scholar 

  • Ehrlich P: On immunity with special reference to cell life. Proc R Soc Lond [Biol] 66: 424, 1906.

    Google Scholar 

  • Foley EJ: Antigenic properties of methyl cholanthrene induced tumors in mice of the strain of origin. Cancer Res 13: 835, 1953.

    PubMed  CAS  Google Scholar 

  • Gross L: Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3: 326, 1943.

    Google Scholar 

  • Haddsen JW: Levamisole: a synthetic immunopotentiator under evaluation. Memorial Sloan-Kettering Cancer Center Clin Bull 5: 32, 1975.

    Google Scholar 

  • Hellstrom KE, Hellstrom I: Immunological defenses against cancer. Hosp Pract 3: 45, 1970.

    Google Scholar 

  • Hollinshead A: Active Specific Immunotherapy. Immunotherapy of Human Cancer. Raven Press, New York, 1978.

    Google Scholar 

  • Hollinshead A, Stewart T: Specific active immunotherapy and specific active immunoprophylaxis in lung cancer. Basis for cancer therapy 2. Reprinted from Moore M (ed): Advances in Medical Oncology Research and Education. Pergamon Press, Oxford, 1979.

    Google Scholar 

  • Hudson CN: Immunologic aspects of gynecological malignancy. Br J Obstet Gynaecol 86: 154, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Hudson CN : Immunology and immunotherapy of ovarian cancer: ovarian cancer. Adv Biosci 26: 1980.

    Google Scholar 

  • Humphrey LJ, Jewell WR, Murray DR, et al: Immunotherapy for patients with cancer. Ann Surg 173: 47, 1971.

    Article  PubMed  CAS  Google Scholar 

  • Hunter-Craig I, Newton KA, Westburg G, et al: Use of vaccine virus in the treatment of metastatic malignant melanoma. Br Med J 2: 512, 1970.

    Article  PubMed  CAS  Google Scholar 

  • Isaacs A, Lindemann J: Virus interference: the interferon. Proc R Soc Lond [Biol] 147: 258, 1957.

    Article  CAS  Google Scholar 

  • Israel L, Halpern B: Le Cornybacterium parvum dans les cancers avancés: première évaluation de pactirité thérapeutique de cette immunostimuline. Nouv Presse Med 1: 19, 1972.

    PubMed  CAS  Google Scholar 

  • Kersey JH, Spector BD, Good RA: Immunodeficiency and cancer. Adv Cancer. Res 18: 211, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Klein E: Hypersensitivity reactions at tumor sites. Cancer Res 29: 2351, 1969.

    PubMed  CAS  Google Scholar 

  • Knauf S, Auerbach GH: Purification of ovarian tumor associated antigen—in patients with advanced ovarian malignancy. Am J Obstet Gynecol 127: 705, 1977.

    PubMed  CAS  Google Scholar 

  • Lawrence HS: Transfer factor. Adv Immunol 11: 195, 1969.

    Article  PubMed  CAS  Google Scholar 

  • Levi MM: Antigenicity of ovarian and cervical malignancy with a view towards possible immunodiagnosis. Am J Obstet Gynecol 109: 687, 1971.

    Google Scholar 

  • Levin L, McHardy JE, Kurling OM, et al: Tumor antigenicity in ovarian cancer. Br J Cancer 32: 152, 1975.

    Article  PubMed  CAS  Google Scholar 

  • Levis WR, Kraemer KH, Klinger WG, et al: Topical immunotherapy of basal cell carcinoma with dinitrochlorobenzene. Cancer Res 33: 3036, 1973.

    PubMed  CAS  Google Scholar 

  • Male D: Immunology—An Illustrated Outline. Mosby, St. Louis, 1986.

    Google Scholar 

  • Mandell GL, Fisher RI, Bostick F, Young RC: Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal “B” cell function. Am J Med 66: 621, 1979.

    Article  PubMed  CAS  Google Scholar 

  • Marligit G, Gutterman JN, Burgess MA, et al: Immunotherapy. Its possible application in the management of large bowel cancer. Dig Dis 19: 1047, 1974.

    Article  Google Scholar 

  • Mathé G: Active immunotherapy for acute lymphoblastic leukemia. Lancet 1: 697, 1969.

    Article  PubMed  Google Scholar 

  • Mathé G, Weiner RS: Investigation and Stimulation of Immunity in Cancer Patients. Springer-Verlag, New York, 1974.

    Google Scholar 

  • McKhann CF, Gunnarsson A: Approaches to immunotherapy. Cancer 34: 1521, 1974.

    Article  PubMed  Google Scholar 

  • Merigan TC, Regelson W: Interferon induction in man by a synthetic polyanion of defined composition. N Engl J Med 277: 1283, 1967.

    Article  PubMed  CAS  Google Scholar 

  • Miller JFAP, Bastep A, Sprent J, Cheers C: Interaction between lymphocytes in immune response. Cell Immunol 2: 469, 1971.

    Article  PubMed  CAS  Google Scholar 

  • Mitchell MS, Kohorn EI: Cell mediated immunity and blocking factor in ovarian cancer. Obstet Gynecol 48: 590, 1976.

    PubMed  CAS  Google Scholar 

  • Morton DL: BCG immunotherapy of malignant melanoma: summary of seven years experience. Ann Surg 180: 635, 1974.

    Article  PubMed  CAS  Google Scholar 

  • Nauts HC, Swift WZ, Coley BL: The treatment of tumor by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 6: 2303, 1946.

    Google Scholar 

  • Oettgen HF, Old LJ, Farrow J, et al: Effects of transfer factor in cancer patients. J Clin Invest 50: 71a, 1971.

    Google Scholar 

  • Ohazaka W, Purchase HG, Burmaster BR: Protection against Marek’s disease by vaccination with a herpes virus of turkeys. Avian Dis 14: 413, 1970.

    Article  Google Scholar 

  • Order SE, Donahue V, Knapp R: Immunotherapy of ovarian carcinoma: an experimental model. Cancer 32: 573, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Order SE, Kirkman R, Knapp R: Serologic immunotherapy: results and probable mechanism of action. Cancer 34: 175, 1974.

    Article  PubMed  CAS  Google Scholar 

  • Paluch E, Ioachim H: Lung carcinoma—reactive antibodies isolated from tumor tissues and pearl effusions of lung cancer patients. J Natl Cancer Inst 61: 319, 1978.

    PubMed  CAS  Google Scholar 

  • Patillo RA, Storey MT, Rukert ACT: Expression of cell mediated immunity and blocking factor using a new line of ovarian cancer cells “in vitro.” Cancer Res. 39: 1185, 1979.

    Google Scholar 

  • Pilch YH, Ramming KP: Transfer of tumor immunity with ribonucleic acid. Cancer 26: 630, 1970.

    Article  PubMed  CAS  Google Scholar 

  • Pilch YH, Ramming KP, Deckers PJ: Induction of anti-cancer immunity with RNA. Ann NY Acad Sci 207: 409, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Plaque RE, Dray S: Monkey to human transfer for delayed hypersensitivity in vitro with RNA extracts. Cell Immunol 5: 30, 1972.

    Article  Google Scholar 

  • Poulton T, Crowther ME, Hay FC: Immune complexes in ovarian cancer. Lancet 2: 12, 1978.

    Google Scholar 

  • Prehn RT, Main JM: Immunity to methycholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769, 1957.

    PubMed  CAS  Google Scholar 

  • Rigby PG: Prolongation of survival of tumor bearing animals by transfer of “immune” RNA with DEAE dextran. Nature 221: 968, 1969.

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg B: Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother Rep 59: 589, 1975.

    PubMed  Google Scholar 

  • Rosenberg B, Van Camp L, Trosko JE: Platinum compound: a new class of potent antitumor agents. Nature 22: 385, 1969.

    Article  Google Scholar 

  • Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF: Postoperative empyema improves survival in lung cancer: documentation and analysis of a natural experiment. N Engl J Med 287: 1013, 1972.

    Article  PubMed  CAS  Google Scholar 

  • Scott MT: Corynebacterium parvum as an immunotherapeutic anti-cancer agent. Semin Oncol 1: 367, 1974.

    CAS  Google Scholar 

  • Simmons RL: Immunospecific regression of methycholanthrene fibrosarcoma with the use of neuraminidase. Surgery 70: 38, 1971.

    PubMed  CAS  Google Scholar 

  • Simmons RL, Rios A: Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy. Natl Cancer Inst Monogr 39: 57, 1973.

    PubMed  CAS  Google Scholar 

  • Simmons RL, Rios A, Ray PK, Lundgren G: Effect of neuraminidase on the growth of methylcholanthrene fibrosarcoma in normal and immunosuppressed syngeneic mice. J Natl Cancer Inst 47: 1087, 1971.

    PubMed  CAS  Google Scholar 

  • Sjögren HO, Hellstrom I, Bansal SC, Hellstrom KE: Suggestive evidence that “blocking antibodies” of tumor bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci USA. 68: 1372, 1971.

    Article  PubMed  Google Scholar 

  • Sokal JE, Aungst CW, Synderman, M.: Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med 291: 1226, 1974.

    Article  PubMed  CAS  Google Scholar 

  • Sparks FC: Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289: 827, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Sparks FC, O’Connell TX, Lee Y-TN, et al: BCG therapy given as an adjuvant to surgery: prevention of death from metastases from mammary adenocarcinoma in rats. J Natl Cancer Inst 53: 1825, 1971.

    Google Scholar 

  • Stjeruswald J, Levin A: Delayed hypersensitivity: induced regression of human neoplasms. Cancer 28: 628, 1971.

    Article  Google Scholar 

  • Terry WD: Immunotherapy of malignant melanoma. N Engl J Med 303: 1174, 1980.

    Article  PubMed  CAS  Google Scholar 

  • Thor DE, Dray S: Transfer of cell-mediated immunity by immune RNA assessed by migration inhibition. Ann NY Acad Sci 207: 355, 1973.

    Article  PubMed  CAS  Google Scholar 

  • Zbar B, Rapp HJ: Immunotherapy of guinea pig cancer with BCG. Cancer 34 (suppl): 1532, 1974.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Lenox Hill Hospital, 100 East 77th Street, 10021-1883, New York, NY, USA

    Hugh R. K. Barber M.D. (Director)

Authors
  1. Hugh R. K. Barber M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Barber, H.R.K. (1993). Immunotherapy and Immunopotentiation. In: Ovarian Carcinoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9232-3_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-9232-3_28

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4613-9234-7

  • Online ISBN: 978-1-4613-9232-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation